PubMed Health⌕ Search

Biomedical subjects

C Comty

Publications and source records attributed to C Comty.

15 recordsLinked to original sources
PubMed1982

Peritoneal transport of vancomycin in 4 patients undergoing continuous ambulatory peritoneal dialysis.

The pharmacokinetics of vancomycin have been studied in 4 chronic renal failure patients undergoing continuous ambulatory peritoneal dialysis. Patients received 1 g of vancomycin in 2 liters of dialysate during an initial phase, and serum and dialysate samples were collected for vancomycin determination. 54% of the amount introduced into the peritoneal cavity were absorbed systemically during a 6-hour cycle. Peak serum concentrations averaged 23.7 microgram/ml. Mean elimination half-life was calculated to be 66.9 h, and dialysis clearance averaged 2.4 ml/min.

Adult↗
PubMed1981

Pharmacokinetics of gentamicin in patients undergoing continuous ambulatory peritoneal dialysis.

Teh pharmacokinetics of gentamicin were studied in seven chronic renal failure patients undergoing continuous ambulatory peritoneal dialysis. Patients received 100 mg of gentamicin in 2 liters of dialysate during an initial pass, and serum and dialysate samples were collected for gentamicin determination. Approximately 49% of the amount introduced into the peritoneal cavity was absorbed systemically during a 6-h cycle. Subsequent clearance of gentamicin from the serum occurred slowly with an elimination half-life of 36 h. Dialysis clearance of gentamicin during continuous ambulatory peritoneal dialysis was 2.94 ml/min.

Adult↗
PubMed1981

Quinidine pharmacokinetics in continuous ambulatory peritoneal dialysis.

The clearance of quinidine was evaluated in a patient undergoing continuous ambulatory peritoneal dialysis (CAPD). The dialysis clearance of quinidine was 0.793 ml/min which represented only 0.61% of the total body clearance (154.21 ml/min) of the drug. The elimination half-life of quinidine was 5.44 hours. Based on our results, dosage adjustment of quinidine does not appear to be necessary for patients undergoing CAPD.

Arrhythmias, Cardiac↗
PubMed1979

Dietary management of patients with diabetes treated by hemodialysis.

Early experience with the treatment of patients with insulin-dependent diabetes and renal failure by chronic hemodialysis indicated a high mortality and increased incidence of medical complications. Since 1972, a marked improvement in survival and reduction in incidence of complications has been attributed to more rigorous control of fluid overload, hypertension, and blood sugar levels by insulin therapy and careful dietary management. A diet has been developed which combines the diet used by dialysis patients with suitable modifications for the insulin-dependent patient with diabetes. The importance of patient education is stressed in an attempt to improve patient compliance.

Diabetes Mellitus↗
PubMed1975

Depressed in vitro aggregation of platelets of chronic hemodialysis patients (CHDP): a role for cyclic AMP.

1) On log-log-coordiantes a direct correlation has bee shown to exist between plasma cyclic AMP and plasma Cr levels. 2) hemodialysis results in a significant reduction in the arterial plasma cyclic AMP levels, but a return of plasma cyclic AMP to pre-dialysis levels is seen within 30 mins post-dialysis. 3) the dialyzer clearance of cyclic AMP, both in vitro and vivo, is commensurate with its M.W. 4) In vitro platelet aggregation responses, to ADP, EPI, and COLL are not influenced by PRP cell counts between 150,000 and 300,000/mm3. 5) the BT of NC and CHDP are not significantly different, indicating that the in vivo hemostatic properties of the CHDP are otherwise intact. 6)the CHDP have PVPC significantly lower than the NC, a finding commensurate with the usual mold thrombocytopenia of renal failure. 7)the aggreation responses of the CHDP to COLL and to both Lo and Hi concentrations of ADP and EPI are significantly less than those of the NC. 8)A statistically significant inverse correlation between aggregation response and plasma cyclic AMP is observed.

Adenosine Diphosphate↗